MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from sale of
common stock under atm
$4,861,706
Proceeds from the sale of
common stock and...
-$2,250,008
Proceeds from exercise of
stock options
$48,000
Net cash provided by
financing activities
$6,596,617
Canceled cashflow
$563,097
Net change in cash
and cash...
-$6,010,153
Canceled cashflow
$6,596,617
Equity-based compensation
$1,939,896
Interest receivable
-$33,057
Depreciation expense
$6,874
Other assets
-$1,625
Issuance costs for the
sale of common stock...
$291,883
Issuance costs for sale of
common stock under atm
$271,214
Net cash used in
operating activities
-$12,601,666
Canceled cashflow
$1,981,452
Net cash used in
investing activities
-$5,104
Net loss
-$13,237,362
Accounts payable
-$851,805
Accrued liabilities
-$244,171
Prepaid expenses
$157,883
Deferred offering costs
$91,897
Investment in property and
equipment
$5,104
Back
Back
Cash Flow
source: myfinsight.com
Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc. (CVKD)